Annovis Bio, Inc. (ANVS) intrinsic value & 10-year financials
Annovis Bio, Inc. (ANVS) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue reached to $0, with an average return on invested capital of -427.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.99
- Market cap
- $20.4M
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -427.2%
- Free cash flow (FY2025)
- —
ANVS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$28.9M | -$1.40 | — | — | -227.0% |
| FY2024 | $0 | -$24.6M | -$2.31 | — | — | -3159.1% |
| FY2023 | $0 | -$56.2M | -$6.23 | — | — | -546.4% |
| FY2022 | $0 | -$25.3M | -$3.10 | — | — | -69.6% |
| FY2021 | $0 | -$14.5M | -$1.90 | — | — | -55.7% |
| FY2020 | $0 | -$5.5M | -$0.87 | — | — | 1055.0% |
| FY2019 | — | -$991.0K | — | — | — | 12.3% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Annovis Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Annovis Bio, Inc. has historically struggled to out-earn its cost of capital, averaging just -20.3% ROIC.
Annovis Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Annovis Bio, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.